Barcelona, Madrid-based Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital.
The additional proceeds will be used to support the 2017 European launch of its DiagCORE Near Patient Testing system.
Led by Gilde Healthcare, the Series C financing round also drew participation from existing investors, including Kurma Partners; Ysios Capital; Idinvest Partners; Boehringer Ingelheim Venture Fund; Caixa Capital Risc; and Axis.
Led by Jordi Carrera, CEO and co-founder, STAT-Diagnostica is advancing
DiagCORE, a fully integrated molecular and immunoassay diagnostics system that performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48-multiplex capabilities via real-time PCR. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type.
The company plans to target a range of decentralized testing environments with DiagCORE, including critical care and emergency medicine units within hospitals. The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.